51 Pilot study of weekly chemo-hormono-immunotherapy including cisplatin, epirubicin, medroxyprogesterone acetate + rIL-2, followed by docetaxel plus cisplatin in patients with advanced (Stage IIIB-IV) non-small-cell lung cancer (NSCLC) - Mantovani, G.; Massa, E.; Madeddu, C.; Gramignano, G.; Astara, G.; Lusso, M.; Cherchi, V.; Serpe, R. (Lung Cancer (01695002), 2005)